Stock Scorecard



Stock Summary for Legend Biotech Corp (LEGN) - $40.14 as of 11/20/2024 8:22:21 PM EST

Total Score

6 out of 30

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for LEGN

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for LEGN

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for LEGN

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for LEGN

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for LEGN (48 out of 90)

Stock Price Rating (Max of 10) 8
Historical Stock Price Rating (Max of 10) 7
Stock Price Trend (Max of 10) 9
Book Value (Max of 10) 4
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 5
Analyst Strong Buy Ratings (Max of 5) 5
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 10
Price to Earnings (Max of 10) 0

Latest News for for LEGN

Legend Biotech ( LEGN ) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now 11/11/2024 2:55:00 PM
Novavax to Report Q3 Earnings: Here's What to Expect 11/11/2024 1:40:00 PM
Legend Biotech to Host Investor Event During the 66th American Society of Hematology ( ASH ) Annual Meeting and Exposition - Legend Biotech ( NASDAQ:LEGN ) 11/7/2024 12:30:00 PM
Legend Biotech to Unveil Minimal Residual Disease Data from Landmark CARTITUDE-4 Trial in Multiple Myeloma - Legend Biotech ( NASDAQ:LEGN ) 11/5/2024 2:10:00 PM
Viatris to Report Q3 Earnings: What's in the Cards? 11/4/2024 6:44:00 PM
Gilead Science to Report Q3 Earnings: What's in the Cards? 11/4/2024 6:43:00 PM
Legend Biotech Appoints Alan Bash as President of CARVYKTI® 11/4/2024 12:30:00 PM
Wall Street Analysts Believe Legend Biotech ( LEGN ) Could Rally 90.83%: Here's is How to Trade 10/24/2024 1:55:00 PM
Legend Biotech to Establish New, State-of-the-Art Cell Therapy Research and Development Facility in Philadelphia - Legend Biotech ( NASDAQ:LEGN ) 10/3/2024 11:30:00 AM
Legend Biotech to Establish New, State-of-the-Art Cell Therapy Research and Development Facility in Philadelphia 10/3/2024 11:30:00 AM

Financial Details for LEGN

Company Overview

Ticker LEGN
Company Name Legend Biotech Corp
Country USA
Description Legend Biotech Corporation, a clinical-stage biopharmaceutical company, is dedicated to the discovery and development of new cell therapies for oncology and other indications in North America and internationally.
Sector Name LIFE SCIENCES
Industry Name PHARMACEUTICAL PREPARATIONS
Most Recent Quarter 6/30/2024
Next Earnings Date N/A

Stock Price History

Last Day Price 40.14
Price 4 Years Ago 28.16
Last Day Price Updated 11/20/2024 8:22:21 PM EST
Last Day Volume 2,240,087
Average Daily Volume 1,614,498
52-Week High 70.13
52-Week Low 37.40
Last Price to 52 Week Low 7.33%

Valuation Measures

Trailing PE N/A
Industry PE 22.60
Sector PE 40.32
5-Year Average PE -29.88
Free Cash Flow Ratio 36.49
Industry Free Cash Flow Ratio 12.03
Sector Free Cash Flow Ratio 27.97
Current Ratio Most Recent Quarter 4.84
Total Cash Per Share 1.10
Book Value Per Share Most Recent Quarter 6.08
Price to Book Ratio 6.28
Industry Price to Book Ratio 5.31
Sector Price to Book Ratio 20.88
Price to Sales Ratio Twelve Trailing Months 13.47
Industry Price to Sales Ratio Twelve Trailing Months 11.82
Sector Price to Sales Ratio Twelve Trailing Months 7.11
Analyst Buy Ratings 10
Analyst Strong Buy Ratings 10

Share Statistics

Total Shares Outstanding 183,450,000
Market Capitalization 7,363,683,000
Institutional Ownership N/A

Dividends

Ex-Dividend Date N/A
Last Dividend Amount 0.00
Current Dividend Amount 0.00
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth -16.11%
Reported EPS 12 Trailing Months -1.92
Reported EPS Past Year -0.94
Reported EPS Prior Year -2.96
Net Income Twelve Trailing Months -285,014,000
Net Income Past Year -518,254,000
Net Income Prior Year -446,349,000
Quarterly Revenue Growth YOY 66.90%
5-Year Revenue Growth 42.15%
Operating Margin Twelve Trailing Months -0.44

Balance Sheet

Total Cash Most Recent Quarter 201,684,000
Total Cash Past Year 1,277,713,000
Total Cash Prior Year 786,031,000
Net Cash Position Most Recent Quarter -89,875,000
Net Cash Position Past Year 996,385,000
Long Term Debt Past Year 281,328,000
Long Term Debt Prior Year 260,932,000
Total Debt Most Recent Quarter 291,559,000
Equity to Debt Ratio Past Year 0.82
Equity to Debt Ratio Most Recent Quarter 0.80
Total Stockholder Equity Past Year 1,251,371,000
Total Stockholder Equity Prior Year 744,312,000
Total Stockholder Equity Most Recent Quarter 1,159,002,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months -196,646,000
Free Cash Flow Per Share Twelve Trailing Months -1.07
Free Cash Flow Past Year -415,998,000
Free Cash Flow Prior Year -222,304,000

Options

Put/Call Ratio 0.12
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD -2.02
MACD Signal -1.70
20-Day Bollinger Lower Band 38.57
20-Day Bollinger Middle Band 50.30
20-Day Bollinger Upper Band 62.02
Beta 0.11
RSI 32.39
50-Day SMA 52.87
150-Day SMA 52.78
200-Day SMA 49.22

System

Modified 11/19/2024 5:19:17 AM EST